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Abstract Measles virus (MV), a member of the family Para-
myxoviridae, encodes C and V non-structural proteins. To clar-
ify the functions of MV C and V proteins, HeLa cell lines
constitutively expressing C or V protein were established. We
found that expression of V protein inhibited interferon (IFN)-
K/L signaling but not IFN-Q signaling. C protein had no inhib-
itory e¡ect on IFN signaling in our experimental condition.
Degradation of selective signal transducers and activators of
transcription (STAT) proteins was not observed in HeLa cells
expressing V protein. In contrast, tyrosine phosphorylation of
both STAT1 and STAT2 was inhibited in these cells after IFN-L
stimulation.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Interferons (IFNs) are secreted from cells infected with vi-
ruses and play important roles in innate immunity. Both IFN-
K/L and IFN-Q can induce an antiviral state in cells through
the Janus kinase-signal transducers and activators of tran-
scription (JAK-STAT) pathway [1]. Following the binding
of IFN-K/L to the type I IFN receptor, receptor-associated
tyrosine kinases JAK1 and Tyk2 are activated, which in
turn phosphorylate STATs, STAT1 and STAT2 [2^4]. Ac-
cording to the sequential activation model, STAT2 and
STAT1 are activated in this order [5]. Phosphorylated
STAT1 and STAT2 proteins form heterodimers, which mi-
grate to the nucleus and associate with p48 to form the active
IFN-stimulated gene factor 3 (ISGF3) complex. ISGF3 binds
to IFN-stimulated response elements (ISREs) and thereby ac-
tive transcription of IFN-K/L-responsive genes. On the other
hand, IFN-Q uses a similar but distinct pathway. Following
the binding of IFN-Q to its receptor, JAK1 and JAK2 are
activated, which in turn phosphorylate STAT1. Phosphorylat-
ed STAT1 protein forms a homodimer, termed Q-activated
factor, that migrates to the nucleus where it binds to speci¢c
cis-acting Q-activated sequences (GASs) to activate the tran-
scription of IFN-Q-responsive genes. In both cases, IFN-in-
ducible gene products such as dsRNA-dependent protein ki-
nase (PKR) and the 2P-5P oligoadenylate synthetases induce
cells to an antiviral state.
Viruses have evolved to have a variety of di¡erent molec-
ular mechanisms to block IFN signaling and thereby circum-
vent the host immune response [6^9]. For example, it has been
shown that several paramyxoviruses in the genus Rubulavirus
circumvent IFN signaling through the action of their V pro-
teins [10^28]. The V proteins of simian virus 5 (SV5), mumps
virus, and SV41 block IFN signaling by targeting STAT1 for
degradation, while the V protein of human parain£uenza virus
type 2 targets STAT2 for degradation. Other paramyxoviruses
in the genus Respirovirus, such as Sendai virus and human
parain£uenza virus type 3, block IFN signaling by a distinct
mechanism [12,29^39]. The Sendai virus C protein blocks
IFN-K/L and IFN-Q signaling by inhibiting phosphorylation
of STAT1. Recently, it has been shown that the Sendai virus
C protein completely inhibits phosphorylation of STAT2 [40].
In addition, the Nipah virus (the genus Henipavirus) V pro-
tein blocks IFN-K/L and IFN-Q signaling by preventing
STAT1 and STAT2 activation and nuclear accumulation
[41]. In other report, the Nipah virus V, W and C proteins
and Newcastle disease virus V protein have been reported to
have IFN-antagonist activity [42]. Recently, it has been shown
that the mumps virus V protein associates with RACK1 re-
sulting in dissociation of STAT1 from the IFN-K receptor
complex [43]. The carboxy-terminal region of STAT1K is
not necessary for its ubiquitination and degradation caused
by the mumps virus V protein [44].
Measles virus (MV), a member of the family Paramyxovir-
idae, genus Morbillivirus, causes an acute exanthematous dis-
ease that kills about one million children per year. The MV
genome encodes the non-structural C and V proteins in addi-
tion to the structural proteins [45]. Recently, Yokota et al.
have reported that cells infected with MV displayed suppres-
sion of the IFN-K-induced antiviral state [46]. However, it was
not known which MV protein blocks IFN signaling.
Here, we show that MV V protein blocks the IFN-K/L-
induced antiviral state, but not the IFN-Q-induced state, and
that MV V protein does not induce the degradation of STATs
as was shown for paramyxoviruses in the genus Rubulavirus,
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but instead inhibits phosphorylation of both STAT1 and
STAT2.
2. Materials and methods
2.1. Antibodies
A peptide designated C20-40 (NH2-CWPSRKPWQHGQKYQ-
TTQDRTE-COOH) corresponding to the amino acids at positions
20^40 of MV C protein of the IC-B strain was synthesized and
coupled to keyhole limpet hemocyanin (KLH). A cysteine residue
found in the C20-40 peptide was used for conjugation to KLH. An-
other synthetic peptide designated V279-299 (NH2-CRTDTGVDTRI-
WYHNLPEIPE-COOH) corresponding to the carboxy-terminus of
MV V protein of the IC-B strain was synthesized and coupled to
KLH. Rabbits (two rabbits for each peptide) were injected with the
peptides and bled, and sera were tested for the presence of anti-pep-
tide antibodies by enzyme-linked immunosorbent assay using the free
peptides as antigens. Anti-STAT1K/L rabbit polyclonal antibody (no.
sc-346; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
STAT2 rabbit polyclonal antibody (no. sc-476; Santa Cruz Biotech-
nology), anti-phospho-(Tyr701) STAT1 (anti-tyrosine-phosphorylated
(pY)-STAT1) (no. 9171; Cell Signaling Technology, Beverly, MA,
USA), anti-phospho-(Tyr689) STAT2 (anti-pY-STAT2) (no. 07-224;
Upstate Biotechnology, Lake Placid, NY, USA), and anti-phospho-
(Ser727) STAT1 (anti-serine-phosphorylated (pS)-STAT1) (no. 06-
802; Upstate Biotechnology) were used in Western blotting analysis.
2.2. Plasmids
To synthesize cDNA encoding the C protein open reading frame
(ORF), polymerase chain reaction (PCR) was carried out using
CBam1 (GCGGATCCGGCACGCCATGTCAAAAACG) and
CBam2 (GCGGATCCTCAGGAGCTCGTGGATCTCC) primers
and the full-length cDNA clone of the IC-B strain of wild-type MV
as a template [47,48]. Since the mRNA for the V protein contains an
extra guanine (G) residue by the mechanism of RNA editing [49], two-
step PCR was carried out to synthesize cDNA encoding the V protein
ORF. Two fragments containing an extra G residue were synthesized
using a set of VBam1 (GCGGATCCGGAGACGATGGCAGAA-
GAGC) and VBam2 (AATCTCGCGTCTGTGCCCCTT) primers
and a set of VBam3 (AAGGGGCACAGACGCGAGATT) and
VBam4 (GCGAATTCGGATCCTCATTATTCTGGGATCTCGG)
primers and the full-length cDNA clone of the IC-V strain of wild-
type MV as a template [47,48]. Then, the two PCR fragments were
mixed and a second PCR was carried out using VBam1 and VBam4
primers. Resulting PCR fragments containing the C and V ORF were
digested with BamHI and cloned into the BamHI site of plasmid
pKS336 (generous gift from K. Sakai, National Institute of Infectious
Diseases, Tokyo, Japan), to make pKS-C (C protein), and pKS-V
(V protein).
2.3. Establishment of stable transformants
Establishment of cells stably expressing V or C protein was done as
described previously [37]. Brie£y, 1U106 HeLa cells per 9-cm-diame-
ter dish were transfected with 10 Wg of pKS-C or pKS-V plasmids
using a mammalian transfection kit (Stratagene, La Jolla, CA, USA.).
Two days later, the medium was replaced with Dulbecco’s modi¢ed
Eagle’s medium containing 2 Wg/ml of blasticidin-S (Funakosi, Tokyo,
Japan). Several colonies grown in the selection medium were picked
up and used in this study.
2.4. Antiviral activity of IFNs
Antiviral activity of IFNs was measured as previously described [37]
with minor modi¢cation. Brie£y, cells plated at a density of 3U105/
well in 24-well plates were treated with human IFN-L or IFN-Q at 0,
10, 100 or 1000 IU/well for 24 h. The cells were washed with phos-
phate-bu¡ered saline and infected with encephalomyocarditis (EMC)
virus at a multiplicity of infection of 0.04 for 60 min at 37‡C, and
further incubated in the same serum-free medium without IFN. For
viral cytopathic e¡ect assay, cells were ¢xed and stained with 0.5%
amido black.
2.5. Reporter gene assay
For luciferase assays, 0.5 Wg of plasmid pMx-luc [50] containing
ISRE sequence or pGAS-TA-luc (Clontech, Palo Alto, CA, USA)
containing GAS sequence along with pSEAP-Control (Clontech)
were cotransfected into parental HeLa or HeLa-V cells grown in
six-well plates (2U105cells/well) with standard calcium phosphate pro-
cedures. At 20^24 h post transfection, the cells were incubated with or
without IFN-L or IFN-Q at 1000 IU/ml for 0, 2, 4 or 6 h. Portions of
cell lysates were assayed for luciferase activities using the luciferase
assay system (Promega, Madison, WI, USA) and a MiniLumat
LB9506 luminometer (Berthold, Pforzheim, Germany). To monitor
transfection e⁄ciency, a portion of each cell supernatants was assayed
for secreted alkaline phosphatase (SEAP) by using the SEAP assay kit
(Toyobo, Osaka, Japan).
2.6. Western blotting
Cells were lysed in a lysis bu¡er (50 mM Tris^HCl, pH 7.4, 150 mM
NaCl, 0.6% NP40, 1 mM Na3VO4, 4 mM PMSF, 1 mM EDTA, 1 mM
NaF) and disrupted by sonication for 1 min. After centrifugation,
lysates were electrophoresed by sodium dodecyl sulfate^polyacryl-
amide gels. Proteins in the gel were transferred to PVDF membrane
(Millipore, Bedford, MA, USA). The protein was detected using
horseradish peroxidase-conjugated goat anti-rabbit antibodies (Amer-
sham, Piscataway, NJ, USA) and Western Blotting Luminol Reagent
(Santa Cruz Biotechnology) or biotinylated anti-rabbit Ig (Amer-
sham) and streptavidin^alkaline phosphatase (Amersham).
3. Results
3.1. Establishment of stable cell lines constitutively expressing
MV C or V protein
To establish cell lines constitutively expressing C or V pro-
tein, either the C or V protein ORF was inserted into the
plasmid pKS336 and transfected into HeLa cells. In the
V-expressing plasmid, the nucleotide sequence preceding the
ATG initiation codon was changed from CCGATG to AC-
GATG according to Kozak’s rule to favor exclusive synthesis
of V protein and prevent leaky scanning for the synthesis of
C protein. Several cell lines were established, and two cell lines
were selected as described in Section 2 for further analysis.
One of these (HeLa-C) expresses MV C protein, and the other
(HeLa-V) expresses MV V protein. The expression of C or
V protein was con¢rmed by immunoblotting analysis using
antisera speci¢c for C (Fig. 1A, lane 3) or V protein (Fig.
1A, lane 5). No C protein was detected in HeLa (Fig. 1A,
lane 1) and HeLa-V (Fig. 1A, lane 2) cells. Likewise, no V
protein was detected in HeLa (Fig. 1A, lane 4) and HeLa-C
(Fig. 1A, lane 6) cells in our experimental condition.
3.2. MV V protein counteracts IFN-K/L-mediated induction of
an antiviral state
To see the e¡ect of C and V proteins on establishment of an
antiviral state, cells were incubated with IFN-L or IFN-Q at 0,
10, 100 or 1000 IU/well for 24 h, and challenged with EMC
virus. Parental HeLa cells incubated with IFN-L were pro-
tected from EMC virus challenge (Fig. 1B). HeLa-C cells in-
cubated with IFN-L were also protected from EMC virus
challenge (Fig. 1B), indicating that C protein did not counter-
act IFN-K/L-mediated induction of an antiviral state. In sharp
contrast, HeLa-V cells incubated with IFN-L were completely
sensitive to EMC virus challenge (Fig. 1B). IFN-K treatment
gave the same results (data not shown). These results indi-
cated clearly that MV V protein counteracted IFN-K/L-medi-
ated induction of an antiviral state.
For IFN-Q-mediated induction, parental HeLa cells incuba-
ted with IFN-Q were protected from EMC virus challenge
(Fig. 1C). Similarly, HeLa-C as well as HeLa-V cells incuba-
ted with IFN-Q were also protected from EMC virus chal-
lenge, indicating that neither C nor V protein of MV could
counteract IFN-Q-mediated induction of an antiviral state
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(Fig. 1C). We con¢rmed these results by using other HeLa cell
clones expressing C or V proteins (data not shown).
3.3. MV V protein blocks IFN-K/L but not IFN-Q signaling
To test the e¡ect of V protein on IFN-K/L-mediated signal-
ing, an IFN-K/L-responsive plasmid pMx-luc and a control
plasmid pSEAP-Control were cotransfected into parental
HeLa and HeLa-V cells. The relative luciferase activities in-
creased linearly with incubation time in IFN-L-treated paren-
tal HeLa cells (Fig. 2A). In contrast, no increase in relative
luciferase activity was found in HeLa-V cells treated with
IFN-L (Fig. 2A), indicating that V protein blocked IFN-K/L
signaling. To test the e¡ect of V protein on IFN-Q-mediated
signaling, an IFN-Q-responsive plasmid pGAS-TA-luc and the
control plasmid pSEAP-Control were cotransfected into pa-
rental HeLa and HeLa-V cells. IFN-Q treatment of parental
HeLa and HeLa-V cells resulted in the induction of the GAS-
luciferase reporter gene activity (Fig. 2B), indicating that
V protein did not block the IFN-Q signaling pathway.
3.4. MV V protein does not induce degradation of STAT1 or
STAT2 but instead inhibits phosphorylation of STAT2 and
STAT1
It has been shown that V proteins of paramyxoviruses in
the genus Rubulavirus induce degradation of STAT1 or
STAT2 [10^28]. On the other hand, V protein of Nipah virus
and C protein of Sendai virus have been shown to inhibit
tyrosine or serine phosphorylation of STAT1 without degra-
dation of STAT1 or STAT2 [33,37,41]. The degradation of
STAT1 was also reported in mouse embryo ¢broblast cells
infected with Sendai virus [31]. The suppression of tyrosine
phosphorylation of STAT1 is thought to contribute to the
blockade of IFN-K/L signaling. The suppression of serine
phosphorylation of STAT1 was reported for Sendai virus-in-
fected cells [12,36], although serine phosphorylation of STAT1
is not important for transactivation function of ISGF3. Very
recently, Sendai virus C protein has been shown to inhibit
tyrosine phosphorylation of STAT2 completely [40].
To see whether V protein induces the selective degradation
of STAT1 or STAT2 as reported for other paramyxoviruses,
immunoblotting was performed using antibodies speci¢c for
STAT1 or STAT2. As shown in Fig. 3, total amounts of
STAT1K/L at time 0 between parental HeLa and HeLa-V cells
were almost the same (Fig. 3A,B). Similarly, total amounts of
STAT2 at time 0 between parental HeLa and HeLa-V cells
were almost the same (Fig. 3C). These results indicated that
V protein of MV does not target STAT1 or STAT2 for pro-
teasome degradation. Upon IFN-L treatment, total amounts
 
 
Fig. 1. IFN-induced antiviral states of parental, C-expressing, and V-expressing HeLa cells. A: Extract lysates (10 Wg of protein) from parental
HeLa (lanes 1 and 4), HeLa-V (lanes 2 and 5) and HeLa-C (lanes 3 and 6) cells were subjected to sodium dodecyl sulfate^polyacrylamide gel
electrophoresis, followed by Western blotting analysis with C-speci¢c antiserum (lanes 1^3) or with V-speci¢c antiserum (lanes 4^6) using the al-
kaline phosphatase method and molecular weight standards (in thousand) are indicated. Cells in 24-well plates were incubated for 24 h with
various concentrations of IFN-L (B) and IFN-Q (C), and were challenged with EMC virus. Cells that survived the challenge infection and re-
mained attached to the plates were ¢xed and stained.
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of STAT1K/L (Fig. 3A,B) and STAT2 (Fig. 3C) increased
gradually in parental HeLa cells as previously reported
[34,37]. On the other hand, the levels of STAT1K/L (Fig.
3A,B) and STAT2 (Fig. 3C) in HeLa-V cells remained con-
stant on IFN-L treatment.
Next, the e¡ect of V protein expression on tyrosine or ser-
ine phosphorylation of STAT1 was examined. Parental HeLa
and HeLa-V cells were left unstimulated or treated with IFN-
L and then lysed at the times indicated. As shown in Fig. 3A,
pY-STAT1K/L increased within 5 min of IFN-L treatment in
parental HeLa cells as previously reported [34,39]. In contrast,
tyrosine phosphorylation of STAT1K/L was strongly inhibited
in HeLa-V cells after IFN-L stimulation (Fig. 3A). The e¡ect
of V protein expression on serine phosphorylation of STAT1
was also examined. As shown in Fig. 3B, pS-STAT1K gradu-
ally increased up to 24 h after IFN-L treatment in parental
HeLa cells. In contrast, serine phosphorylation of STAT1K
was not detected in HeLa-V cells after IFN-L stimulation
(Fig. 3B).
Finally, tyrosine phosphorylation of STAT2 in parental
HeLa and HeLa-V cells was examined. As shown in Fig.
3C, pY-STAT2 was increased within 5 min of IFN-L treat-
ment and was prolonged for up to 24 h in parental HeLa cells.
In contrast, pY-STAT2 was below the detection level in
HeLa-V cells at any incubation periods upon IFN-L stimula-
tion as reported for cells expressing Sendai virus C protein
[40]. These results suggest crucial roles of STAT1 and STAT2
in the inhibitory e¡ect of MV V protein on IFN-K/L signaling.
4. Discussion
By expressing C or V protein of MV in HeLa cells, we
demonstrated that V protein but not C protein counteracts
the IFN-K/L-mediated induction of an antiviral state by
blocking IFN-K/L signaling. C proteins are encoded by viruses
belonging to the genus Respirovirus (for example, Sendai vi-
rus), the genus Morbillivirus (for example, MV) and the genus
Henipavirus (Nipah virus) among the family Paramyxoviri-
dae. The C protein of Sendai virus was shown to counteract
the IFN-mediated induction of an antiviral state by blocking
IFN signaling [29,33,37]. These observations led us to examine
whether MV C protein can block IFN signaling. Also, during
the progress of our research, the C protein of Nipah virus was
Fig. 2. Expression of the V protein inhibits IFN-K/L but not IFN-Q
signaling. A: Parental (solid bar) and V-expressing HeLa cells (open
bar) were transfected with an ISRE-luciferase reporter gene and
control pSEAP plasmid. The cells were treated with 1000 U of
IFN-L per ml for 0, 2, 4 or 6 h. Relative expression levels were nor-
malized by SEAP activity and expressed as fold activation. B: Pa-
rental (solid bar) and V-expressing HeLa cells (open bar) were
transfected with a GAS-luciferase reporter gene and control pSEAP
plasmid. The cells were treated with 1000 U of IFN-Q per ml for 0,
2, 4 or 6 h. Relative expression levels were normalized by SEAP ac-
tivity and expressed as fold activation.
Fig. 3. E¡ects of the V protein on tyrosine or serine phosphoryla-
tion of STAT1 or STAT2. Parental and V-expressing HeLa cells
treated with 1000 IU per ml of IFN-L were incubated for the indi-
cated times and harvested. Total cell extracts were subjected to en-
hanced chemiluminescence^Western blot analysis with anti-phos-
pho-(Tyr701)-STAT1 (A), anti-phospho-(Ser727)-STAT1 (B) or anti-
phospho-(Tyr690)-STAT2 (C). Total amounts of STAT1 or STAT2
were estimated with anti-STAT1 (sc-346) or anti-STAT2 (sc-476) us-
ing the alkaline phosphatase method.
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reported to have IFN-antagonist activity [42]. However, MV
C protein did not inhibit IFN signaling in our experimental
condition, although we cannot rule out the possibility that
high-level expression of MV C protein might inhibit IFN sig-
naling to some extent. The C proteins of Sendai virus, Nipah
virus and MV are all small in size and highly basic, but their
amino acid sequences are divergent [42,51]. MV C protein
might be a prototype, and the C proteins of Sendai virus
and Nipah virus might have evolved to acquire an additional
activity to block host IFN signaling. A recombinant MV with-
out the expression of the C protein has been generated, and
this virus showed alterations in growth and pathogenicity [52^
54]. Thus, MV C protein could have yet unidenti¢ed func-
tion(s) di¡erent from blocking IFN signaling.
We found that MV V protein inhibits IFN-K/L but not
IFN-Q signaling without inducing selective degradation of
STAT1 or STAT2. Thus, MV V protein is di¡erent from
those of the genus Rubulavirus, which inhibit IFN signaling
by targeting STAT1 or STAT2 for degradation [10^28]. Since
Nipah virus V protein blocks IFN signaling by preventing
STAT activation without degradation of STATs [41], MV V
protein is similar to the Nipah virus V protein in this respect.
However, the Nipah virus V protein di¡ers from MV V pro-
tein in that it can block IFN-Q signaling as well as IFN-K/L
signaling [41]. It is interesting that the IFN-K/L-induced but
not the IFN-Q-induced antiviral state was abrogated in HeLa-
V cells, although phosphorylation of both STAT1 and STAT2
was inhibited by MV V protein. It should be noted that the
phosphorylation of STAT2 was completely blocked, while the
phosphorylation of STAT1 was strongly but not completely
blocked. This result suggests that inhibition of tyrosine phos-
phorylation of STAT2 accounts for the blockade of IFN-K/L
signaling by MV V protein. Although pY-STAT1 is the com-
mon component of both IFN-K/L and IFN-Q signaling, IFN
receptor complexes responsible for phosphorylation of STAT1
are di¡erent in IFN-K/L and IFN-Q signaling pathways.
Therefore, it is not surprising that MV V protein inhibits
IFN-K/L signaling but not IFN-Q signaling. We are currently
examining IFN-Q signaling in parental HeLa and HeLa-V cells
in detail. We do not know at present why di¡erent paramyxo-
virus V proteins use di¡erent strategies to counteract IFN
signaling in spite of structural similarities among V proteins
of MV, Nipah virus and those of the genus Rubulavirus,
which all have a well-conserved cysteine-rich domain at their
carboxy-terminal ends [41,49,51]. The N-terminal domain of
the V proteins might be responsible for determining a path-
way to inactivate STAT [13]. Making chimeric V proteins
among these V proteins would give us some clues to identify
the domain or amino acid sequence important for these di¡er-
ences.
It has been reported that a recombinant MV de¢cient in the
expression of the V protein shows restricted growth phenotype
and pathogenicity in infected rodents [52,54,55]. These di¡er-
ences might be attributable to the anti-IFN signaling activity
of the MV V protein. Naniche et al. reported that particular
strains of MV induced less IFN and were sensitive to the
action of IFN [56]. It is interesting to compare the anti-IFN
signaling activity of the V proteins of di¡erent MV strains.
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